ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Highlights
RMD's net income has soared by 54% YoY and by 21% QoQ
The EPS has soared by 52% YoY and by 21% from the previous quarter
Resmed's quick ratio has increased by 28% YoY but it has decreased by 5% from the previous quarter
Resmed's debt has decreased by 14% QoQ but it has increased by 2.2% YoY
The price to earnings (P/E) is 22% higher than the 5-year quarterly average of 36.5
Key stats
What are the main financial stats of RMD
Market
Shares outstanding
144.9M
Market cap
$27.81B
Enterprise value
$28.65B
Valuations
Price to earnings (P/E)
44.53
Price to book (P/B)
11.12
Price to sales (P/S)
9.37
EV/EBIT
37.04
EV/EBITDA
30
EV/Sales
9.69
Earnings
Revenue
$2.96B
EBIT
$773.47M
EBITDA
$954.84M
Free cash flow
$706.93M
Per share
EPS
$4.31
Free cash flow per share
$4.9
Book value per share
$17.26
Revenue per share
$20.49
TBVPS
$15.58
Balance sheet
Total assets
$4.59B
Total liabilities
$2.09B
Debt
$1.3B
Equity
$2.5B
Working capital
$920.7M
Liquidity
Debt to equity
0.52
Current ratio
2.53
Quick ratio
1.56
Net debt/EBITDA
0.88
Margins
EBITDA margin
32.3%
Gross margin
58.1%
Net margin
21%
Operating margin
27.4%
Efficiency
Return on assets
14.1%
Return on equity
27.2%
Return on invested capital
30%
Return on capital employed
19.4%
Return on sales
26.2%
Dividend
Dividend yield
0.81%
DPS
$1.56
Payout ratio
36.2%
RMD stock price
How has the Resmed stock price performed over time
Financial performance
How have Resmed's revenue and profit performed over time
Revenue
$2.96B
Gross profit
$1.72B
Operating income
$809.66M
Net income
$621.67M
Gross margin
58.1%
Net margin
21%
RMD's net income has soared by 54% YoY and by 21% QoQ
RMD's operating income is up by 40% YoY and by 14% QoQ
Resmed's net margin has increased by 35% YoY and by 19% QoQ
RMD's operating margin is up by 23% year-on-year and by 12% since the previous quarter
Growth
What is Resmed's growth rate over time
Valuation
What is Resmed stock price valuation
P/E
44.53
P/B
11.12
P/S
9.37
EV/EBIT
37.04
EV/EBITDA
30
EV/Sales
9.69
The EPS has soared by 52% YoY and by 21% from the previous quarter
The price to earnings (P/E) is 22% higher than the 5-year quarterly average of 36.5
RMD's P/B is 57% above its 5-year quarterly average of 7.1 and 12% above its last 4 quarters average of 9.9
RMD's equity is up by 21% year-on-year and by 11% since the previous quarter
The P/S is 56% higher than the 5-year quarterly average of 6.0 and 17% higher than the last 4 quarters average of 8.0
The company's revenue rose by 13% YoY and by 2.3% QoQ
Efficiency
How efficient is Resmed business performance
Resmed's ROE has increased by 33% YoY and by 15% from the previous quarter
The ROA has increased by 32% YoY and by 18% from the previous quarter
The ROS has increased by 23% YoY and by 15% from the previous quarter
The company's return on invested capital rose by 15% QoQ and by 14% YoY
Dividends
What is RMD's dividend history
DPS
$1.56
Dividend yield
0.81%
Payout ratio
36.2%
Recent dividends
Financial health
How did Resmed financials performed over time
The company's total assets is 119% higher than its total liabilities
Resmed's quick ratio has increased by 28% YoY but it has decreased by 5% from the previous quarter
The current ratio has grown by 23% YoY but it has contracted by 4.9% from the previous quarter
Resmed's debt is 48% lower than its equity
Resmed's debt to equity has decreased by 22% QoQ and by 15% YoY
RMD's equity is up by 21% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated
quarterly, unless otherwise specified.